LogicBio Therapeutics (LOGC) PT Lowered to $2 at JMP Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mailGet Alerts LOGC Hot Sheet
Price: $7.06 --0%
Rating Summary:
6 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Rating Summary:
6 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Join SI Premium – FREE
JMP Securities analyst Silvan Tuerkcan lowered the price target on LogicBio Therapeutics (NASDAQ: LOGC) to $2.00 (from $16.00) while maintaining a Market Outperform rating.
You May Also Be Interested In
- Uber Inc. (UBER) PT Lowered to $90 at Bernstein SocGen Group
- Knife River Corp. (KNF) PT Raised to $59 at RBC Capital
- Assurant (AIZ) PT Raised to $345 at Keefe, Bruyette & Woods
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
